

Cancer

**A study exploring the safety and efficacy of Atezolizumab in combination with Obinutuzumab or Rituximab anti-CD20 therapy in participants with Relapse/Refractory Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM)**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
11 Countries

**Trial Identifier**  
2016-003579-22 MO39107

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

Atezolizumab + Rituximab in R/R MZL and Atezolizumab + Obinutuzumab in R/R MCL and WM

**F. Hoffman La Roche (Switzerland)**  
Sponsor

**Phase 2**  
Phase

**2016-003579-22 MO39107**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
Male/Female

**Age**  
≥ 18 years

**Healthy Volunteers**  
No

This study is a multicenter, open-label, phase 2 study of atezolizumab (A) in combination with rituximab (R) or Obinutuzumab (G), all administered by intravenous infusion (IV) in participants with refractory and/or relapsed Marginal Zone Lymphoma and Waldenström Macroglobulinemia or Mantle Cell Lymphoma. This study will evaluate the safety and efficacy of the above combinations as well as pharmacokinetic parameters, biomarkers and occurrence of anti-drug antibodies of A, R and G.